Robyn R. Young
About
Robyn R. Young is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Robyn R. Young has authored 24 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Robyn R. Young's work include Advanced Breast Cancer Therapies (12 papers), Cancer Treatment and Pharmacology (12 papers) and Prostate Cancer Treatment and Research (5 papers). Robyn R. Young is often cited by papers focused on Advanced Breast Cancer Therapies (12 papers), Cancer Treatment and Pharmacology (12 papers) and Prostate Cancer Treatment and Research (5 papers). Robyn R. Young collaborates with scholars based in United States, Italy and United Kingdom. Robyn R. Young's co-authors include Denise A. Yardley, Stefan Glück, W.M. Moseley, Howard A. Burris, Andreas Schneeweiß, Celestia S. Higano, Nadia Harbeck, Steven Fischkoff, Luis de la Cruz‐Merino and Haythem Ali and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
In The Last Decade
Robyn R. Young
24 papers receiving 337 citations
Peers
Robyn R. Young
Pedro Exman United States
Nicole Caixeiro Australia
Chester Kao United States
Alexander Golf Germany
Laurence Crouzet France
James M. Randall United States
Jingbo Yi United States
Olga Oikonomidou United Kingdom
Citations per year, relative to Robyn R. Young Robyn R. Young (= 1×)
peers
Pedro Exman
Countries citing papers authored by Robyn R. Young
Since
Specialization
Citations
This map shows the geographic impact of Robyn R. Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robyn R. Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robyn R. Young more than expected).
Fields of papers citing papers by Robyn R. Young
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robyn R. Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robyn R. Young. The network helps show where Robyn R. Young may publish in the future.
Co-authorship network of co-authors of Robyn R. Young
This figure shows the co-authorship network connecting the top 25 collaborators of Robyn R. Young. A scholar is included among the top collaborators of Robyn R. Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robyn R. Young. Robyn R. Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yardley, Denise A., Robyn R. Young, Kerin B. Adelson, et al.. (2021). A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer. 22(3). 269–278.
2.
Yardley, Denise A., Robyn R. Young, Kerin B. Adelson, et al.. (2021). Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC). Cancer Research. 81(4_Supplement). PS11–29.
3.
Besse, Benjamin, Jessica Menis, Paolo Bironzo, et al.. (2020). LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. Annals of Oncology. 31. S1211–S1212.
4.
Yardley, Denise A., N. W. Peacock, Brooke Daniel, et al.. (2020). Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 180(3). 647–655.
5.
Yardley, Denise A., William H. Liggett, Mark Mainwaring, et al.. (2019). A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Clinical Breast Cancer. 20(2). 89–97.
6.
Yardley, Denise A., Rob Coleman, Pierfranco Conté, et al.. (2018). nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology. 29(8). 1763–1770.
7.
Yardley, Denise A., Robert L. Coleman, Pierfranco Conté, et al.. (2017). Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial. Cancer Research. 77(4_Supplement). P5–15.
8.
Hainsworth, John D., et al.. (2016). Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy. Breast Cancer Research and Treatment. 160(1). 41–49.
9.
Yardley, Denise A., Suzanne F. Jones, N. W. Peacock, et al.. (2015). Abstract OT2-1-07: A phase II study with orteronel as monotherapy in patients with androgen receptor (AR) expressing metastatic breast cancer (MBC). Cancer Research. 75(9_Supplement). OT2–1.
10.
Yardley, Denise A., Michelle Melisko, Andres Forero, et al.. (2015). METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 33(15_suppl). TPS1110–TPS1110.
11.
Burris, Howard A., Fabienne Lebrun, Hope S. Rugo, et al.. (2013). Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial. Cancer. 119(10). 1908–1915.
12.
Sachdev, Jasgit C., Jeffrey W. Allen, Lee S. Schwartzberg, et al.. (2013). Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 31(15_suppl). 1068–1068.
13.
Yardley, Denise A., Gabriel N. Hortobágyi, Fabienne Lebrun, et al.. (2013). Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology. 31(26_suppl). 155–155.
14.
Yardley, Denise A., Gabriel N. Hortobágyi, Fabienne Lebrun, et al.. (2013). Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology. 31(15_suppl). 553–553.
15.
Rugo, Hope S., J. Thaddeus Beck, José Baselga, et al.. (2012). BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. Journal of Clinical Oncology. 30(27_suppl). 125–125.
16.
Young, Robyn R., et al.. (2012). Abstract OT3-3-07: Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer.. Cancer Research. 72(24_Supplement). OT3–3.
17.
Hortobágyi, Gabriel N., Robyn R. Young, Mark Karwal, et al.. (2010). A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice‐daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 116(10). 2301–2306.
18.
Small, Eric J., Celestia S. Higano, N. Simon Tchekmedyian, et al.. (2006). Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. Journal of Clinical Oncology. 24(18_suppl). 4609–4609.
19.
Herrington, Jon D., et al.. (2000). Randomized, Multicenter Comparison of Oral Granisetron and Oral Ondansetron for Emetogenic Chemotherapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(11). 1318–1323.
20.
Fields, Scott Z., Daniel R. Budman, Robyn R. Young, et al.. (1996). Phase I study of high-dose etoposide phosphate in man.. PubMed. 18(5). 851–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Pedro Exman Breakdown of academic impact, for papers by Nicole Caixeiro Breakdown of academic impact, for papers by Alberto Carretero-González Breakdown of academic impact, for papers by Chester Kao Breakdown of academic impact, for papers by Alexander Golf Breakdown of academic impact, for papers by Laurence Crouzet Breakdown of academic impact, for papers by James M. Randall Breakdown of academic impact, for papers by Concepción Fernández‐Chacón Breakdown of academic impact, for papers by Jingbo Yi Breakdown of academic impact, for papers by Olga Oikonomidou